The educational content for this programme has been designed by a steering committee of leading myeloproliferative neoplasm (MPN) specialists, in collaboration with Novartis.





The MPN Leaders Programme is organised and funded by Novartis Pharmaceuticals UK Ltd and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code. Prescribing information will be available throughout the programme for all Novartis brands mentioned. Participation in the programme will be funded by Novartis (delegate travel, accommodation and reasonable expenses will be covered in the event of a face-to-face meeting). The Steering Committee has been offered an honorarium for their involvement in this programme.